Denise Scots-Knight - 01 Jan 2024 Form 3 Insider Report for Mereo Biopharma Group plc (MREO)

Role
Chief Executive Officer
Signature
/s/ Christine Fox, by power of attorney
Issuer symbol
MREO
Transactions as of
01 Jan 2024
Net transactions value
$0
Form type
3
Filing time
02 Jan 2024, 16:15:18 UTC
Previous filing
04 Dec 2023
Next filing
26 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MREO American Depositary Shares representing Ordinary Shares 559,213 01 Jan 2024 Direct F1, F8
holding MREO American Depositary Shares representing Ordinary Shares 1,200 01 Jan 2024 Direct F1, F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MREO Share Options (Right to buy) 01 Jan 2024 American Depositary Shares 308,949 $8.63 Direct F1, F2
holding MREO Share Options (Right to buy) 01 Jan 2024 American Depositary Shares 87,500 $5.40 Direct F1, F2
holding MREO Share Options (Right to buy) 01 Jan 2024 American Depositary Shares 87,500 $3.00 Direct F1, F2
holding MREO Share Options (Right to buy) 01 Jan 2024 American Depositary Shares 175,000 $1.84 Direct F1, F3
holding MREO Share Options (Right to buy) 01 Jan 2024 American Depositary Shares 520,000 $2.72 Direct F1, F4
holding MREO Share Options (Right to buy) 01 Jan 2024 American Depositary Shares 1,100,000 $1.40 Direct F1, F5
holding MREO Share Options (Right to buy) 01 Jan 2024 American Depositary Shares 1,150,000 $1.01 Direct F1, F6
holding MREO Performance Based Restricted Stock Unit 01 Jan 2024 American Depositary Shares 470,150 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F2 This award is fully vested and exercisable.
F3 25% of the shares underlying this share option vested and became exercisable on February 20, 2021, with the remainder vesting in equal monthly installments for the three years thereafter.
F4 25% of the shares underlying this share option vested and became exercisable on February 1, 2022, with the remainder vesting in equal monthly installments for the three years thereafter.
F5 25% of the shares underlying this share option vested and became exercisable on January 14, 2023, with the remainder vesting in equal monthly installments for the three years thereafter.
F6 25% of the shares underlying this share option will vest and become exercisable on January 25, 2024, with the remainder vesting in equal monthly installments for the three years thereafter.
F7 Each performance based restricted stock unit ("PSU") represents the conditional right to receive one ADS and shall vest upon satisfaction of four escalating ADS price threshold values over a two year performance period. The number included in column 3 of Table II reflects the number of PSUs eligible for vesting. If a minimum ADS price threshold is not met, such PSUs may vest at zero ADSs.
F8 Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per share, of the Issuer.
F9 Represents 1,200 ADSs jointly owned by Reporting Person and her spouse.

Remarks:

Exhibit 24 - Power of Attorney